Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Boston Scientific (BSX) Q4 Earnings Miss, Margins Decline
by Zacks Equity Research
Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q3
by Zacks Equity Research
STERIS' (STE) third-quarter fiscal 2021 results reflect strong performance by all three of its reporting segments despite the coronavirus-led economic crisis.
PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results benefit from strong segmental performance.
Haemonetics (HAE) Q3 Earnings Top Estimates, Margin Contracts
by Zacks Equity Research
Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.
IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise
by Zacks Equity Research
IDEXX (IDXX) registeres strong contribution from its CAG business in the fourth quarter despite pandemic-induced challenges.
Why Abbott (ABT) Might be Well Poised for a Surge
by Zacks Equity Research
Abbott (ABT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Abbott's (ABT) Nutrition & Diabetes Care Beat COVID-19 Woes
by Zacks Equity Research
Within pediatric nutrition, Abbott (ABT) registers U.S. sales growth led by increased market share of Similac infant formula brand.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.
Onmicell (OMCL) Q4 Earnings Beat Estimates, Margin Contracts
by Zacks Equity Research
Omnicell's (OMCL) fourth-quarter 2020 revenues rose 0.36% year over year to $249.2 million, improving 16.1% sequentially.
The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, Abbott Laboratories, Starbucks and Target
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Netflix, Bristol-Myers Squibb, Abbott Laboratories, Starbucks and Target
Top Research Reports for Netflix, Bristol-Myers & Abbott
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Bristol-Myers Squibb (BMY), and Abbott Laboratories (ABT).
Abbott (ABT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
Strong signs of rebound in base sales volumes make us optimistic about VIVO, XRAY, and PDCO's results.
Durable Goods Orders For December Rose Lower-than-Expected
by Zacks Equity Research
Durable Goods Orders For December Rose Lower-than-Expected
Abbott (ABT) Q4 Earnings Top, Diagnostic Test Sales Solid
by Zacks Equity Research
Within Diabetes Care, Abbott (ABT) reports strong sales banking on growing demand for sensor-based continuous glucose monitoring system, FreeStyle Libre.
Pre-Markets Sell Off Ahead of Big Q4 Earnings
by Mark Vickery
It seems a new round of profit-taking is manifesting itself ahead of what will be the single-most consequential day of earnings season so far.
Abbott (ABT) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 6.62% and 8.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
5 Incredible Perfect Earnings Charts
by Tracey Ryniec
It's not easy to beat every quarter on earnings for five years, including during a global pandemic. These companies have done it.
QIAGEN (QGEN) Announces COVID-19 Test Updates as Cases Rise
by Zacks Equity Research
QIAGEN (QGEN) along with with Australia-based digital diagnostics company, Ellume develops QIAreach SARS-CoV-2 Antigen Test.
Boston Scientific's (BSX) DBS System Gets FDA's Clearance
by Zacks Equity Research
The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.
Demand for COVID-19 Tests to Drive Abbott (ABT) Q4 Earnings
by Zacks Equity Research
Within EPD, Abbott (ABT) is expected to have witnessed visible signs of rebound through Q4.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
Federal, Private Tie-Ups Boost COVID-19 Testing Volume
by Urmimala Biswas
The Department of Health and Human Services (HHS) promises over $22 billion of funding.
What's in Store for UnitedHealth (UNH) This Earnings Season?
by Zacks Equity Research
UnitedHealth's (UNH) earnings results are likely to reflect solid contribution from its segments, namely Healthcare and Optum, partly offset by higher claim costs.
What's in Store for Intuitive Surgical's (ISRG) Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter earnings are likely to reflect solid performance at Instruments & Accessories segment.